Browsing by Author "Rothbart, Scott B."

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    Global lysine methylome profiling using systematically characterized affinity reagents
    (Springer Nature, 2023-01-07) Berryhill, Christine A.; Hanquier, Jocelyne N.; Doud, Emma H.; Cordeiro‑Spinetti, Eric; Dickson, Bradley M.; Rothbart, Scott B.; Mosley, Amber L.; Cornett, Evan M.; Biochemistry and Molecular Biology, School of Medicine
    Lysine methylation modulates the function of histone and non-histone proteins, and the enzymes that add or remove lysine methylation—lysine methyltransferases (KMTs) and lysine demethylases (KDMs), respectively—are frequently mutated and dysregulated in human diseases. Identification of lysine methylation sites proteome-wide has been a critical barrier to identifying the non-histone substrates of KMTs and KDMs and for studying functions of non-histone lysine methylation. Detection of lysine methylation by mass spectrometry (MS) typically relies on the enrichment of methylated peptides by pan-methyllysine antibodies. In this study, we use peptide microarrays to show that pan-methyllysine antibodies have sequence bias, and we evaluate how the differential selectivity of these reagents impacts the detection of methylated peptides in MS-based workflows. We discovered that most commercially available pan-Kme antibodies have an in vitro sequence bias, and multiple enrichment approaches provide the most comprehensive coverage of the lysine methylome. Overall, global lysine methylation proteomics with multiple characterized pan-methyllysine antibodies resulted in the detection of 5089 lysine methylation sites on 2751 proteins from two human cell lines, nearly doubling the number of reported lysine methylation sites in the human proteome.
  • Thumbnail Image
    Item
    Lysine Methylation Regulators Moonlighting outside the Epigenome
    (Elsevier, 2019-09-19) Cornett, Evan M.; Ferry, Laure; Defossez, Pierre-Antoine; Rothbart, Scott B.; Biochemistry and Molecular Biology, School of Medicine
    Landmark discoveries made nearly two decades ago identified known transcriptional regulators as histone lysine methyltransferases; since then the field of lysine methylation signaling has been dominated by studies of how this small chemical posttranslational modification regulates gene expression and other chromatin-based processes. However, recent advances in mass spectrometry-based proteomics have revealed that histones are just a subset of the thousands of eukaryotic proteins marked by lysine methylation. As the writers, erasers, and readers of histone lysine methylation are emerging as a promising therapeutic target class for cancer and other diseases, a key challenge for the field is to define the full spectrum of activities for these proteins. Here we summarize recent discoveries implicating non-histone lysine methylation as a major regulator of diverse cellular processes. We further discuss recent technological innovations that are enabling the expanded study of lysine methylation signaling. Collectively, these findings are shaping our understanding of the fundamental mechanisms of non-histone protein regulation through this dynamic and multi-functional posttranslational modification.
  • Thumbnail Image
    Item
    A physical basis for quantitative ChIP-sequencing
    (Elsevier, 2020-11-20) Dickson, Bradley M.; Tiedemann, Rochelle L.; Chomiak, Alison A.; Cornett, Evan M.; Vaughan, Robert M.; Rothbart, Scott B.; Biochemistry and Molecular Biology, School of Medicine
    ChIP followed by next-generation sequencing (ChIP-Seq) is a key technique for mapping the distribution of histone posttranslational modifications (PTMs) and chromatin-associated factors across genomes. There is a perceived challenge to define a quantitative scale for ChIP-Seq data, and as such, several approaches making use of exogenous additives, or "spike-ins," have recently been developed. Herein, we report on the development of a quantitative, physical model defining ChIP-Seq. The quantitative scale on which ChIP-Seq results should be compared emerges from the model. To test the model and demonstrate the quantitative scale, we examine the impacts of an EZH2 inhibitor through the lens of ChIP-Seq. We report a significant increase in immunoprecipitation of presumed off-target histone PTMs after inhibitor treatment, a trend predicted by the model but contrary to spike-in-based indications. Our work also identifies a sensitivity issue in spike-in normalization that has not been considered in the literature, placing limitations on its utility and trustworthiness. We call our new approach the sans-spike-in method for quantitative ChIP-sequencing (siQ-ChIP). A number of changes in community practice of ChIP-Seq, data reporting, and analysis are motivated by this work.
  • Thumbnail Image
    Item
    A Read/Write Mechanism Connects p300 Bromodomain Function to H2A.Z Acetylation
    (Elsevier, 2019-11-22) Colino-Sanguino, Yolanda; Cornett, Evan M.; Moulder, David; Smith, Grady C.; Hrit, Joel; Cordeiro-Spinetti, Eric; Vaughan, Robert M.; Krajewski, Krzysztof; Rothbart, Scott B.; Clark, Susan J.; Valdés-Mora, Fátima; Biochemistry and Molecular Biology, School of Medicine
    Acetylation of the histone variant H2A.Z (H2A.Zac) occurs at active regulatory regions associated with gene expression. Although the Tip60 complex is proposed to acetylate H2A.Z, functional studies suggest additional enzymes are involved. Here, we show that p300 acetylates H2A.Z at multiple lysines. In contrast, we found that although Tip60 does not efficiently acetylate H2A.Z in vitro, genetic inhibition of Tip60 reduces H2A.Zac in cells. Importantly, we found that interaction between the p300-bromodomain and H4 acetylation (H4ac) enhances p300-driven H2A.Zac. Indeed, H2A.Zac and H4ac show high genomic overlap, especially at active promoters. We also reveal unique chromatin features and transcriptional states at enhancers correlating with co-occurrence or exclusivity of H4ac and H2A.Zac. We propose that differential H4 and H2A.Z acetylation signatures can also define the enhancer state. In conclusion, we show both Tip60 and p300 contribute to H2A.Zac and reveal molecular mechanisms of writer/reader crosstalk between H2A.Z and H4 acetylation through p300.
  • Thumbnail Image
    Item
    A Role for Widely Interspaced Zinc Finger (WIZ) in Retention of the G9a Methyltransferase on Chromatin*.
    (ASBMB, 2015-10-23) Simon, Jeremy M.; Parker, Joel S.; Liu, Feng; Rothbart, Scott B.; Ait-Si-Ali, Slimane; Strahl, Brian D.; Jin, Jian; Davis, Ian J.; Mosley, Amber L.; Pattenden, Samantha G.; Department of Biochemistry and Molecular Biology, IU School of Medicine
    Background: G9a-GLP lysine methyltransferases mono- and di-methylate histone H3 lysine 9 (H3K9me2).Results: Widely interspaced zinc finger (WIZ) regulates H3K9me2 levels through a mechanism that involves retention of G9a on chromatin.Conclusion: The G9a-GLP-WIZ complex has unique functions when bound to chromatin that are independent of the H3K9me2 mark.Significance: Combining pharmacologic and genetic manipulations is essential to any translational hypotheses related to G9a function.
  • Thumbnail Image
    Item
    Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling
    (American Association for the Advancement of Science, 2024) Chomiak, Alison A.; Tiedemann, Rochelle L.; Liu, Yanqing; Kong, Xiangqian; Cui, Ying; Wiseman, Ashley K.; Thurlow, Kate E.; Cornett, Evan M.; Topper, Michael J.; Baylin, Stephen B.; Rothbart, Scott B.; Biochemistry and Molecular Biology, School of Medicine
    DNA methyltransferase inhibitor (DNMTi) efficacy in solid tumors is limited. Colon cancer cells exposed to DNMTi accumulate lysine-27 trimethylation on histone H3 (H3K27me3). We propose this Enhancer of Zeste Homolog 2 (EZH2)-dependent repressive modification limits DNMTi efficacy. Here, we show that low-dose DNMTi treatment sensitizes colon cancer cells to select EZH2 inhibitors (EZH2is). Integrative epigenomic analysis reveals that DNMTi-induced H3K27me3 accumulates at genomic regions poised with EZH2. Notably, combined EZH2i and DNMTi alters the epigenomic landscape to transcriptionally up-regulate the calcium-induced nuclear factor of activated T cells (NFAT):activating protein 1 (AP-1) signaling pathway. Blocking this pathway limits transcriptional activating effects of these drugs, including transposable element and innate immune response gene expression involved in viral defense. Analysis of primary human colon cancer specimens reveals positive correlations between DNMTi-, innate immune response-, and calcium signaling-associated transcription profiles. Collectively, we show that compensatory EZH2 activity limits DNMTi efficacy in colon cancer and link NFAT:AP-1 signaling to epigenetic therapy-induced viral mimicry.